Apexcella Biomedical has developed unique ApexNK® expansion technology that enables the mass production of NK cells with high purity and high cytotoxicity to provide affordable allogeneic NK or CAR-NK cell therapies to respond to unmet medical needs. It will initiate the Phase I trials of allogeneic ApexNK® cells with therapeutic antibodies to treat lymphoma or solid tumors in 2025. The first CAR-ApexNK candidate is expected to file IND in 2026.
選單